Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole and Trimethoprim (Double Strength)
Bactrim DS
Teva-trimel
Apo Sulfamethoxazole Tab 500mg
Sulfatrim
Septra Grape
Sulfamethoxazole
Sulfatrim DS
Sulfamethoxazole and Trimethoprim for Injection, USP
Protrin Tab
Sulfamethoxazole and Trimethoprim Injection, BP
Sulfamethoxazole and Trimethoprim Double Strength
Apo-sulfatrim Oral Suspension
Riva-sep DS
Roubac Tab 80/400
Septra Pediatric Suspension
Septra Injection
Sulfamethoxazole Tab 500mg
Nu-cotrimox Tab 400/80mg
Roubac Tab 160/800
Sulfamethox-TMP DS
Teva-trimel DS
Nu-cotrimox Sus 40/8mg/ml
Nu-cotrimox-DS Tab 800/160mg
Protrin Df Tab
Septra DS Tablets
Trisulfa Tab
Sulfameth/Trimeth-DS
Bactrim Roche Inj
Sulfamethoxazole and Trimethoprim DS
SULFAMETHOXAZOLE and TRIMETHOPRIM
Sulfamethoxazole and Trimethoprim
Bactrim Roche Tab
Septra DS
SULFAMETHOXAZOLE AND TRIMETHOPRIM double strength
Trisulfa DS Tab
Sulfamethoxazole and Trimethoprim Tablets
Septra
Bactrim
Trisulfa S Suspension
sulfamethoxazole-trimethoprim (SMZ)
Indication
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863] In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
